Research programme: coronavirus hybrid vaccines - NuGenerex Immuno-Oncology
Alternative Names: 2019-nCOV hybrid vaccines - NuGenerex Immuno-Oncology; 2019-nCOV specific Li-Key-hybrids vaccinesLatest Information Update: 28 Mar 2024
At a glance
- Originator NuGenerex Immuno-Oncology
- Class COVID-19 vaccines; Peptide vaccines; Synthetic vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 06 Feb 2020 Coronavirus hybrid vaccines - NuGenerex Immuno-Oncology is available for licensing as of 06 Feb 2020. www.generex.com
- 06 Feb 2020 Early research in COVID-2019-infections (Prevention) in USA (Parenteral)
Development Overview
Introduction
Hybrid vaccines based on the Li-Key peptide vaccine technology are being developed by NuGenerex Immuno-Oncology (previously Antigen Express and wholly-owned subsidiary of Generex) for the prevention of COVID-2019 infections. The proprietary technology utilises the 4-amino acid Li-Key peptide which is chemically linked to synthetic peptides that mimic as essential epitope of the virus. The Li-Key peptide by interacting with the allosteric site of MHC Class II molecules causes displacement of the existing antigens and anchors the chemically linked viral epitope to the antigen binding domain. This interaction allows the hybrid vaccine to bypass all requirements for antigen processing and results in enhanced activation of CD4+ T cells and improves long-term immunologic memory. The hybrid vaccine is composed of naturally occurring amino acids which helps in prevention of adverse reactions. Early stage development is ongoing in the US.
NuGenerex Immuno-Oncology is seeking partners for the development of hybrid vaccines for prevention of COVID-2019 infections [1] .
As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections (Prevention) in USA (Parenteral).
Patent Information
The use of Antigen Express's Li-Key technology in the development of immunotherapeutic vaccines is covered by a granted patent in Japan, international counterparts in the US, Europe, Australia, and China, and a pending application in Canada [2] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class COVID-19 vaccines, Peptide vaccines, Synthetic vaccines
- Target CD4-positive T lymphocyte
- Mechanism of Action CD4-positive T lymphocyte stimulants; Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Prevention | No development reported (Research) | USA | Parenteral / unspecified | NuGenerex Immuno-Oncology | 28 Mar 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| NuGenerex Immuno-Oncology | Originator | USA |
| NuGenerex Immuno-Oncology | Owner | USA |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| NuGenerex Immuno-Oncology | COVID 2019 infections | Unspecified | - | 06 Feb 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Parenteral) Updated 28 Mar 2024 |
| 06 Feb 2020 | Licensing Status | Coronavirus hybrid vaccines - NuGenerex Immuno-Oncology is available for licensing as of 06 Feb 2020. www.generex.com [1] Updated 17 Feb 2020 |
| 06 Feb 2020 | Phase Change | Early research in COVID-2019-infections (Prevention) in USA (Parenteral) [1] Updated 17 Feb 2020 |
| 01 Feb 2012 | Patent Information | NuGenerex Immuno-Oncology has patent pending for Li-Key technology in Canada [2] Updated 17 Feb 2020 |
| 01 Feb 2012 | Patent Information | NuGenerex Immuno-Oncology has patent protection for Li-Key technology in USA, Europe, Australia, China [2] Updated 17 Feb 2020 |
References
-
Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines.
Media Release -
Generex Announces Patent Award for its Core Vaccine Technologies in Japan.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG